{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Chemotherapy\") was discontinued at the recommendation of the Independent Data', 'Monitoring Committee (IDMC) after review of available efficacy data which', 'demonstrated shorter overall survival in the rovalpituzumab tesirine arm compared with', 'the topotecan control arm. At the time enrollment was halted, 444 DLL3 high ( 75%', 'tumor cells staining positive for DLL3 with VENTANA Rabbit IHC (SP347) DLL3', 'assay) subjects had enrolled on the trial. The IDMC recommended that investigators and', 'subjects make individual decisions as to whether or not to continue treatment based on', 'patient level response. The results of the TAHOE study did not adversely impact the', 'safety profile for rovalpituzumab tesirine.', '19', 'Section 3.5 Benefits and Risks', 'Add: new second paragraph', 'As of 30 June 2018, 1246 subjects have received study medication in the rovalpituzumab', 'tesirine clinical program; an estimated 1039 subjects (with SCLC or other DLL3- -', 'expressing solid tumors) have received at least 1 dose of rovalpituzumab tesirine at doses', 'ranging from 0.05 mg/kg to 0.8 mg/kg on a q3w schedule and 0.3 mg/kg to 0.4 mg/kg on', 'a q6w schedule.', 'Section 3.5 Benefits and Risks', 'Second paragraph, first and second sentence previously read:', 'The most frequent treatment-emergent adverse event (TEAE) terms considered related to', 'rovalpituzumab tesirine have included fatigue (35%), pleural effusion (31%) and', 'peripheral edema (27%), while the most frequent, related TEAE groups of Grade 3 or', 'higher have included thrombocytopenia (12%), serosal effusions (11%), and skin', 'reactions (8%). 9 In addition, preclinical toxicology studies conducted in the rat and the', 'cynomolgus monkey have identified bone marrow, lung, and kidney as potential sources', 'of clinical adverse events (AEs) (AbbVie Stemcentrx data on file).', '161']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'Among subjects with SCLC treated with rovalpituzumab tesirine 0.3 mg/kg q6w, 96.8%', 'of subjects reported at least 1 adverse event. The most frequently reported adverse events', 'among subjects with SCLC treated with rovalpituzumab tesirine 0.3 mg/kg q6w were', 'decreased appetite (28.0%), photosensitivity reaction (27.7%), oedema peripheral', '(27.2%), dyspnoea (26.6%), and nausea (25.6%). Important identified risks following', 'treatment with rovalpituzumab tesirine include: pleural effusions (33.9%), pericardial', 'effusions (16.7%), generalized edema (2.7%) and photosensitivity reactions (27.7%).', 'Important potential risks following treatment with rovalpituzumab tesirine include', 'pneumonitis (1%). The following adverse events of special interest have also been', 'identified: cutaneous reactions (48.7%), thrombocytopenia and hemorrhage events', '(28%), edema (33.8%), hypoalbuminemia (16.2%), hepatotoxicity (19.3%),', 'nephrotoxicity (5.9%), anemia (19.7%), neutropenia (9.2%) and infusion related reaction', '(0.2%). In addition, preclinical toxicology studies conducted in the rat and the', 'cynomolgus monkey have identified bone marrow, lung, and kidney as potential sources', 'of clinical adverse events (AEs) (AbbVie Investigator Brochure v7).', 'Section 4.0 Study Objectives', 'Previously read:', 'The primary objective of this study is to evaluate if rovalpituzumab tesirine improves', 'progression-free and overall survival in subjects with extensive-stage SCLC who have', 'ongoing clinical benefit (SD, PR, or CR) following the completion of 4 cycles of', 'first-line, platinum-based chemotherapy (cisplatin or carboplatin plus irinotecan or', 'etoposide) compared to placebo.', 'The secondary objectives are to evaluate rovalpituzumab tesirine anti-tumor activity by', 'determining objective response rate (ORR), clinical benefit rate (CBR), and duration of', 'responses (DOR), and to assess change in patient reported outcomes (PRO) with', 'EORTC QLQ-C30/LC-13 questionnaires.', '162']\n\n###\n\n", "completion": "END"}